EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Placental growth factor before 11 weeks for screening of preterm preeclampsia: The PreMoM study

Rocío López Mármol iD, José Alejandro Ávila Cabreja, Teresa de Haro Romero iD, Catalina de Paco Matallana iD, Olga Ocón Hernández iD, Otilia González-Vanegas iD, Pilar Carretero Lucena, María Paz Carrillo, Juan Luis Delgado iD, Valeria Rolle, Uzay Gormus, Liza Oraha und 2 weitere

Acta Obstetricia et Gynecologica Scandinavica · 2025

DOI: 10.1111/aogs.70026 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Obstetricia et Gynecologica Scandinavica, 2025. Verfasst von Rocío López Mármol und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Hospital Universitario Virgen de las Nieves, Granada, Spain. Hauptthemen laut MEDLINE: Placenta Growth Factor, Pre-Eclampsia. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, iMaterna Foundation, Roche Diagnostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Our objective was to compare the predictive performance of the Fetal Medicine Foundation (FMF) competing‐risk model for preterm preeclampsia (PE) screening using placental growth factor (PlGF) measurements obtained at 11–13 +6 weeks versus before 11 weeks of gestation. Material and Methods This multicenter prospective cohort study included women with singleton pregnancies attending their routine first‐trimester assessment (11 +0 to 13 +6 weeks) in four hospitals across Spain from 2021 to 2023. Maternal characteristics, biophysical parameters (mean arterial pressure and uterine artery pulsatility index), and biochemical markers (PlGF measured twice in each woman, before 11 weeks and between 11 and 13 +6 weeks) were assessed. Risk assessment for preterm PE was estimated by the FMF algorithm. Predictive performance was evaluated by comparing detection rates (DR) at different fixed screen‐positive rates (SPR), area under the receiver‐operating characteristic curve (AUROC), and calibration plots. Statistical adjustments were made to account for prophylactic aspirin use.

Results

The study population comprised 3448 women, including 19 (0.55%) who developed preterm preeclampsia and 47 (1.36%) who developed term preeclampsia. At 10% SPR, the detection rates (adjusted for aspirin use) were highest for the model incorporating PlGF between 11 and 13 +6 weeks (72.9%; 95% CI, 42.2%–90.9%), compared to models with PlGF before 11 weeks (66.4%; 95% CI, 39.9%–85.4%) and without PlGF (66.0%; 95% CI, 39.3%–85.3%). Similar trends were observed at higher SPR thresholds. The best discrimination (AUROC: 0.863; 95% CI, 0.754–0.971) and calibration were also achieved by the model using PlGF between 11 and 13 +6 weeks.

Conclusions

PlGF measured before 11 weeks did not improve preterm PE screening performance. Due to the small number of cases, further validation is needed. Maternal and biophysical markers remain a viable alternative when PlGF is unavailable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Placenta Growth FactorPre-EclampsiaHumansFemalePregnancyAdultProspective StudiesPregnancy Trimester, FirstBiomarkersSpainRisk AssessmentPredictive Value of TestsGestational Age

Stichwörter der Autor:innen

first pregnancy trimestermaternal serum screening testsplacenta growth factorpreeclampsia

Substanzen

Placenta Growth FactorBiomarkersPGF protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.
  • Fundación Pública Andaluza para la Investigación Biosanitaria Andalucía Oriental, Granada, Spain.
  • Clinical Laboratory Management Unit, Hospital Universitario Clínico San Cecilio, Granada, Spain.
  • Department of Obstetrics and Gynecology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
  • Department of Obstetrics and Gynecology, Hospital Universitario San Cecilio, Granada, Spain.

ORCID-Profile: Rocío López Mármol, Teresa de Haro Romero, Catalina de Paco Matallana, Olga Ocón Hernández, Otilia González-Vanegas, Juan Luis Delgado, María M Gil

Förderung

  • Instituto de Salud Carlos III
  • iMaterna Foundation
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Revvity Omics Sweden
  • Fundación BBVA
  • Consejería de Salud y Consumo, Junta de Andalucía

Zitieren

APA

López Mármol, R., Ávila Cabreja, J. A., de Haro Romero, T., de Paco Matallana, C., Ocón Hernández, O., González-Vanegas, O., Carretero Lucena, P., Carrillo, M. P., Delgado, J. L., Rolle, V., Gormus, U., Oraha, L., Gil, M. M., & Molina, F. S. (2025). Placental growth factor before 11 weeks for screening of preterm preeclampsia: The PreMoM study. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.70026

Vancouver

López Mármol R, Ávila Cabreja JA, de Haro Romero T, de Paco Matallana C, Ocón Hernández O, González-Vanegas O, et al. Placental growth factor before 11 weeks for screening of preterm preeclampsia: The PreMoM study. Acta Obstetricia et Gynecologica Scandinavica. 2025. doi:10.1111/aogs.70026

BibTeX
@article{LpezMrmol2025,
  author = {López Mármol, Rocío and Ávila Cabreja, José Alejandro and de Haro Romero, Teresa and de Paco Matallana, Catalina and Ocón Hernández, Olga and González-Vanegas, Otilia and Carretero Lucena, Pilar and Carrillo, María Paz and Delgado, Juan Luis and Rolle, Valeria and Gormus, Uzay and Oraha, Liza and Gil, María M and Molina, Francisca S},
  title = {Placental growth factor before 11 weeks for screening of preterm preeclampsia: The PreMoM study},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2025},
  doi = {10.1111/aogs.70026}
}
Kostenlos starten →